MiMedx (MDXG)
Market Price (4/23/2026): $3.315 | Market Cap: $490.9 MilSector: Health Care | Industry: Biotechnology
MiMedx (MDXG)
Market Price (4/23/2026): $3.315Market Cap: $490.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.9%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.9%, FCF Yield is 14% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -55% Low stock price volatilityVol 12M is 42% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -74% | Key risksMDXG key risks include [1] its history of financial fraud allegations, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.9%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.9%, FCF Yield is 14% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -55% |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -74% |
| Key risksMDXG key risks include [1] its history of financial fraud allegations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
MiMedx (MDXG) stock has lost about 50% since 12/31/2025 because of the following key factors:
1. Reduction in Medicare Reimbursement Rates for Wound Care Products.
The primary factor driving the stock's decline was the recalibration of Medicare reimbursement rates for skin substitutes, effective January 1, 2026. This change caused significant disruption in the Wound Care market, leading to a slow recovery, decreased claims processing, and increased price competition with "dumped" products at very low prices.
2. Lower-than-expected 2026 Revenue Guidance.
Despite reporting strong fourth-quarter and full-year 2025 results that beat analyst estimates (Q4 2025 EPS of $0.14 vs. $0.09 consensus, and revenue of $118.1 million vs. $106.78 million), MiMedx issued disappointing 2026 revenue guidance. The company projected 2026 net sales between $340 million and $360 million, a substantial decrease from the $419 million reported for the full year 2025. This negative outlook, directly linked to the Medicare reimbursement changes, signaled anticipated revenue and gross margin pressure, causing the stock to decline by 1.3% the day after the announcement and drift 21.7% lower in the subsequent 45 days.
Show more
1. Reduction in Medicare Reimbursement Rates for Wound Care Products.
The primary factor driving the stock's decline was the recalibration of Medicare reimbursement rates for skin substitutes, effective January 1, 2026. This change caused significant disruption in the Wound Care market, leading to a slow recovery, decreased claims processing, and increased price competition with "dumped" products at very low prices.
2. Lower-than-expected 2026 Revenue Guidance.
Despite reporting strong fourth-quarter and full-year 2025 results that beat analyst estimates (Q4 2025 EPS of $0.14 vs. $0.09 consensus, and revenue of $118.1 million vs. $106.78 million), MiMedx issued disappointing 2026 revenue guidance. The company projected 2026 net sales between $340 million and $360 million, a substantial decrease from the $419 million reported for the full year 2025. This negative outlook, directly linked to the Medicare reimbursement changes, signaled anticipated revenue and gross margin pressure, causing the stock to decline by 1.3% the day after the announcement and drift 21.7% lower in the subsequent 45 days.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -51.1% change in MDXG stock from 12/31/2025 to 4/22/2026 was primarily driven by a -58.9% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.77 | 3.31 | -51.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 393 | 419 | 6.4% |
| Net Income Margin (%) | 10.4% | 11.6% | 11.8% |
| P/E Multiple | 24.5 | 10.1 | -58.9% |
| Shares Outstanding (Mil) | 148 | 148 | 0.0% |
| Cumulative Contribution | -51.1% |
Market Drivers
12/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| MDXG | -51.1% | |
| Market (SPY) | -5.4% | 41.2% |
| Sector (XLV) | -5.4% | 46.8% |
Fundamental Drivers
The -52.6% change in MDXG stock from 9/30/2025 to 4/22/2026 was primarily driven by a -68.5% change in the company's P/E Multiple.| (LTM values as of) | 9302025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.98 | 3.31 | -52.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 364 | 419 | 15.1% |
| Net Income Margin (%) | 8.8% | 11.6% | 31.2% |
| P/E Multiple | 32.1 | 10.1 | -68.5% |
| Shares Outstanding (Mil) | 148 | 148 | -0.2% |
| Cumulative Contribution | -52.6% |
Market Drivers
9/30/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| MDXG | -52.6% | |
| Market (SPY) | -2.9% | 36.7% |
| Sector (XLV) | 5.6% | 32.7% |
Fundamental Drivers
The -56.4% change in MDXG stock from 3/31/2025 to 4/22/2026 was primarily driven by a -61.7% change in the company's P/E Multiple.| (LTM values as of) | 3312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.60 | 3.31 | -56.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 349 | 419 | 20.0% |
| Net Income Margin (%) | 12.2% | 11.6% | -4.6% |
| P/E Multiple | 26.3 | 10.1 | -61.7% |
| Shares Outstanding (Mil) | 147 | 148 | -0.8% |
| Cumulative Contribution | -56.4% |
Market Drivers
3/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| MDXG | -56.4% | |
| Market (SPY) | 16.3% | 36.8% |
| Sector (XLV) | 1.6% | 35.0% |
Fundamental Drivers
The -2.9% change in MDXG stock from 3/31/2023 to 4/22/2026 was primarily driven by a -23.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312023 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.41 | 3.31 | -2.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 268 | 419 | 56.3% |
| P/S Multiple | 1.4 | 1.2 | -19.1% |
| Shares Outstanding (Mil) | 114 | 148 | -23.2% |
| Cumulative Contribution | -2.9% |
Market Drivers
3/31/2023 to 4/22/2026| Return | Correlation | |
|---|---|---|
| MDXG | -2.9% | |
| Market (SPY) | 63.3% | 23.4% |
| Sector (XLV) | 18.4% | 20.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MDXG Return | -33% | -54% | 215% | 10% | -30% | -53% | -65% |
| Peers Return | 16% | -32% | 22% | 1% | -5% | -20% | -26% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 88% |
Monthly Win Rates [3] | |||||||
| MDXG Win Rate | 67% | 33% | 67% | 50% | 17% | 0% | |
| Peers Win Rate | 56% | 40% | 58% | 48% | 48% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MDXG Max Drawdown | -39% | -56% | 0% | -37% | -40% | -53% | |
| Peers Max Drawdown | -4% | -49% | -20% | -29% | -30% | -28% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ORGO, IART, SYK, VCEL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/22/2026 (YTD)
How Low Can It Go
| Event | MDXG | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -83.4% | -25.4% |
| % Gain to Breakeven | 501.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -58.2% | -33.9% |
| % Gain to Breakeven | 139.1% | 51.3% |
| Time to Breakeven | 267 days | 148 days |
| 2018 Correction | ||
| % Loss | -86.6% | -19.8% |
| % Gain to Breakeven | 645.2% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -92.2% | -56.8% |
| % Gain to Breakeven | 1175.0% | 131.3% |
| Time to Breakeven | 1,444 days | 1,480 days |
Compare to ORGO, IART, SYK, VCEL
In The Past
MiMedx's stock fell -83.4% during the 2022 Inflation Shock from a high on 9/8/2021. A -83.4% loss requires a 501.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MiMedx (MDXG)
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
AI Analysis | Feedback
Here are 1-2 brief analogies for MiMedx (MDXG):
- Like a specialized Amgen (AMGN) for advanced tissue and wound repair.
- Similar to Organogenesis (ORGO), but focused on placental tissue products for healing.
AI Analysis | Feedback
- EpiFix: A semi-permeable protective barrier membrane used for treating chronic wounds like diabetic foot and pressure ulcers.
- AmnioFix: A semi-permeable protective barrier allograft made from dehydrated human amnion/chorion membrane for surgical recovery applications.
- EpiCord and AmnioCord: Dehydrated human umbilical cord allografts used to provide a protective environment for healing in advanced wound care and surgical recovery.
- AMNIOBURN: A semi-permeable protective barrier allograft specifically used in the treatment of partial-thickness and full-thickness burns.
- mdHACM: A micronized, powder form of AMNIOFIX.
AI Analysis | Feedback
MiMedx (MDXG) sells its products primarily to healthcare organizations and professionals rather than directly to individuals or a few named major corporate customers. Its sales approach, utilizing a direct sales force, independent sales agents, and distributors, indicates a broad customer base across various healthcare sectors. The major categories of customers it serves include:
- Hospitals and Surgical Centers: These institutions utilize MiMedx products for surgical recovery applications, burn treatment (e.g., AMNIOBURN), and advanced wound care within inpatient and outpatient settings.
- Specialized Wound Care Clinics: These facilities are key customers for products like EpiFix, which treats chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
- Sports Medicine and Orthopedic Clinics: These practices use MiMedx's allografts for non-operative sports medicine applications and surgical recovery.
AI Analysis | Feedback
nullAI Analysis | Feedback
Joseph H. Capper, Chief Executive Officer
Mr. Capper joined MiMedx in January 2023. He brings nearly 30 years of experience in MedTech and Life Sciences leadership roles. Mr. Capper previously served as CEO of BioTelemetry, where he led a significant turnaround that culminated in its acquisition by Royal Philips for $2.8 billion. Prior to BioTelemetry, he was President and CEO of both Home Diagnostics and CCS Medical. Earlier in his career, he held several leadership roles at Bayer AG and served as an officer in the U.S. Navy as a naval aviator.
Doug Rice, Chief Financial Officer
Mr. Rice joined MiMedx in July 2023. He has more than a decade of experience in the MedTech industry. Most recently, he served as the CFO of Orthofix Medical. Prior to Orthofix, Mr. Rice was CFO at Vision Source and held various finance leadership roles at McAfee and Concentra. He began his career at PricewaterhouseCoopers and is a Certified Public Accountant.
Ricci S. Whitlow, Chief Operating Officer
Ms. Whitlow joined MiMedx in January 2023. She brings over 30 years of Life Sciences and Pharmaceutical experience, with a background in operational leadership. Her prior roles include President, Clinical Supply Services at Catalent Pharma Solutions, and leadership positions at Optinose, LifeCell, Kinetic Concepts, and Johnson & Johnson.
Kim Moller, Chief Commercial Officer
Ms. Moller was promoted to Chief Commercial Officer in June 2024, having served as Senior Vice President of Sales since August 2020. She has nearly three decades of experience in sales leadership, including successfully executing strategic growth plans for prominent healthcare companies such as 3M and its subsidiaries Acelity and KCI.
William Frank Hulse, General Counsel and Chief Administrative Officer
Mr. Hulse joined MiMedx in December 2019, bringing over two decades of experience in large law firms and life sciences organizations, with significant legal, risk management, compliance, and operational expertise. Before MiMedx, he was a member of Dykema, a national law firm. Prior to that, he held various roles of increasing responsibility at Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.), including Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory, and also served as Division General Counsel.
AI Analysis | Feedback
The key risks to MiMedx (MDXG) primarily stem from its reliance on evolving healthcare reimbursement policies, the highly competitive nature of its market, and ongoing legal and intellectual property challenges.
- Medicare Reimbursement Changes: MiMedx faces significant uncertainty and potential market disruption due to upcoming changes in Medicare reimbursement policies, particularly the "2026 Regulatory Cliff" for its regenerative biomaterial products and skin substitutes. The Centers for Medicare and Medicaid Services (CMS) is implementing new payment approaches, including fixed reimbursement rates and adjustments to Local Coverage Determinations (LCDs), which are anticipated to lead to price pressure and a potential temporary stall in revenue growth. This regulatory shift is a major concern, as the company is highly dependent on the U.S. market. While MiMedx is proactively adapting its product mix and leveraging its platform to manage this transition, it remains a significant near-term headwind, impacting 2026 revenue guidance.
- Intense Market Competition: The regenerative medicine and wound care industries in which MiMedx operates are highly competitive. The company competes with numerous established tissue processors, medical device manufacturers, and new entrants, some of whom offer high-priced, clinically unproven skin substitutes. This intense competition can lead to customer and sales force attrition and necessitates continuous innovation and product differentiation for MiMedx to maintain its market share. Changes in CMS policies, such as the withdrawal of certain LCDs, could also intensify competitive pressures.
- Legal and Intellectual Property (IP) Challenges: MiMedx has a history of legal disputes, including ongoing litigation with competitors and former employees, which results in increased general and administrative expenses and poses risks to the company's reputation. The company’s business relies on its proprietary PURION process and an extensive patent portfolio, which it actively defends through lawsuits against alleged infringers. However, the ability to fully protect its intellectual property is uncertain, and there is an inherent risk of becoming subject to infringement claims from other parties. While past favorable rulings demonstrate their commitment to IP defense, ongoing legal battles can consume significant financial and management resources.
AI Analysis | Feedback
nullAI Analysis | Feedback
MiMedx Group, Inc. (MDXG) operates in several significant addressable markets for its placental tissue allografts, primarily in wound care, surgical recovery, burn treatment, and sports medicine. Here are the estimated addressable market sizes for MiMedx's main products and services: * **Advanced Wound Care and Surgical Markets:** The combined addressable market for MiMedx's products in the United States and Japan is estimated at $3.9 billion. MiMedx itself estimates the combined U.S. wound and surgical market for its products to be currently $2.0 billion ($1.1 billion in wound; $0.9 billion in surgical) and anticipates it will grow at an annual rate of 7-10% from 2023. * **Global Wound Care Market:** This market was valued at USD 24.08 billion in 2025 and is projected to reach USD 33.62 billion by 2033, growing at a CAGR of 4.28% from 2026 to 2033. Another estimate places the global wound care market at USD 22.37 billion in 2025, projected to reach USD 41.22 billion by 2034 with a CAGR of 7.05%. North America held the largest share of this market, accounting for 46.88% in 2025. * **Global Advanced Wound Care Management Market:** This market was estimated to be worth USD 10.65 billion in 2024 and is projected to reach USD 17.50 billion by 2035, with a CAGR of 4.62%. North America is expected to generate the highest demand in this market. Another report valued the global advanced wound care market at USD 13.32 billion in 2025, expecting it to grow to USD 23.33 billion by 2034 with a CAGR of 6.52%. North America dominated with a valuation of USD 5.66 billion in 2025. * **Skin Substitutes Market:** This market, a key segment for MiMedx, is projected to grow from $1.1 billion in 2021 to $2.0 billion by 2026, with a compound annual growth rate (CAGR) of 12%. * **Global Burn Care Market (relevant for AMNIOBURN):** The global burn care market size was valued at USD 2.4 billion in 2023 and is anticipated to reach USD 4.6 billion by 2032, growing at a CAGR of 7.4%. The North America burn care market size in 2023 was valued at USD 915.5 million. The global deep burn treatment market was estimated at $5 billion in 2025 and is projected to exceed $9 billion by 2033, exhibiting a CAGR of approximately 7%. * **Global Amniotic Products Market (relevant for EpiFix, AmnioFix, EpiCord, AmnioCord, mdHACM):** This market was valued at USD 910.78 million in 2023 and is expected to reach USD 1,734.03 million by 2032, growing at a CAGR of 7.42%. The U.S. Amniotic Products Market size was valued at USD 68.48 million in 2023 and holds a market share of around 75% of the global market. Another source states the global amniotic products market is expected to reach USD 1,451.2 million by 2030, with a CAGR of 8.7%. * **Mohs Micrographic Surgery (an application for EpiFix):** There are over 850,000 annual Mohs procedures performed in the U.S., representing a significant market opportunity for products like EpiFix. * **Global Sports Medicine Market (relevant for non-operative sports medicine applications):** This market was valued at USD 7.30 billion in 2024 and is projected to reach USD 15.25 billion by 2033, growing at a CAGR of 8.6% from 2025 to 2033. North America dominated the global market with a revenue share of 51.36% in 2024. * **Global Skin Graft Market:** This market was valued at USD 418.2 million in 2025 and is projected to grow from USD 441.7 million in 2026 to USD 699.2 million by 2034, with a CAGR of 5.90%. North America dominated the global market in 2025, with the regional market valued at USD 306.8 million.AI Analysis | Feedback
MiMedx (MDXG) is expected to drive future revenue growth over the next 2-3 years through several key strategies:- Expansion and Diversification of Surgical Business: MiMedx is focusing on expanding its surgical applications, with the surgical segment demonstrating strong growth, including a 20% increase for the full year 2025 and 25% growth in Q4 2025. This expansion is supported by new commercial hires and recent portfolio additions, such as AmnioFix Thyroid Shield and the licensing of three 510(k)-cleared products for surgical applications, targeting high-growth specialties.
- Launch and Uptake of New Products: The company's wound care segment has experienced strong growth, driven by the successful uptake of recently launched products like EpiExpress and Emerge. MiMedx also plans to continue innovating and diversifying its product portfolio in 2026.
- Continued Investment in Research and Development (R&D) and Clinical Evidence: MiMedx views scientific research as a crucial element of its growth strategy, continuing investments in R&D. This includes ongoing clinical trials, such as a near-completed randomized controlled trial (RCT) for EpiEffect and a planned new RCT for ChorioFix, aimed at long-term differentiation in clinical efficacy.
- Adaptation and Stabilization within the Wound Care Market: Despite near-term disruptions due to Medicare reimbursement changes, MiMedx anticipates a sequential increase in revenue throughout 2026 as the wound care market adjusts and stabilizes. The company expects to recover to historical double-digit top-line growth by 2027, confident in its ability to compete effectively within the new reimbursement framework.
AI Analysis | Feedback
Share Repurchases
- MiMedx's Board of Directors authorized a share repurchase program of up to $100 million over a two-year period, announced on February 25, 2026.
- This program is intended to return capital to shareholders while maintaining flexibility for organic investment and potential mergers and acquisitions.
Share Issuance
- On March 10, 2026, the Chief Commercial Officer acquired 42,845 shares through the vesting of performance stock units, with 21,270 shares withheld for tax obligations.
- The Chief Financial Officer acquired 243,000 shares upon the vesting of performance stock units covering the period from January 1, 2023, to December 31, 2025, with 96,363 shares disposed of to satisfy tax obligations.
- On March 4, 2026, the Chief Executive Officer was awarded 371,094 shares of common stock as restricted stock.
Outbound Investments
- MiMedx's acquisitions amounted to $3.1 million in Q3 2025.
- The total annual value of acquisitions for fiscal year 2024 was $7.9 million.
- The highest quarterly value for acquisitions in the past five years was $5.0 million during Q1 2024.
Capital Expenditures
- Capital expenditures in the most recent quarter totaled -$0.29 million.
- In the last 12 months, capital expenditures were -$1.03 million.
- Projected capital expenditures are $4 million for 2025 and $5 million for 2026, with an expected focus on long-term assets and infrastructure.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| MiMedx Earnings Notes | 12/16/2025 | |
| How Low Can MiMedx Stock Really Go? | 10/17/2025 | |
| MiMedx (MDXG) Debt Comparison | 08/08/2025 | |
| MiMedx (MDXG) Operating Cash Flow Comparison | 08/08/2025 | |
| MiMedx (MDXG) EBITDA Comparison | 08/08/2025 | |
| MiMedx (MDXG) Net Income Comparison | 08/08/2025 | |
| MiMedx (MDXG) Tax Expense Comparison | 08/08/2025 | |
| MiMedx (MDXG) Operating Income Comparison | 08/08/2025 | |
| MiMedx (MDXG) Revenue Comparison | 08/08/2025 | |
| Why MiMedx Stock Moved: MDXG Stock Has Gained 156% Since 2022 Fiscal End, Primarily Due To Favorable Change In Price To Sales Multiple (P/S) | 08/08/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 04/17/2026 |
Trade Ideas
Select ideas related to MDXG.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.75 |
| Mkt Cap | 0.8 |
| Rev LTM | 563 |
| Op Inc LTM | 56 |
| FCF LTM | 25 |
| FCF 3Y Avg | 14 |
| CFO LTM | 52 |
| CFO 3Y Avg | 56 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 16.5% |
| Rev Chg 3Y Avg | 10.8% |
| Rev Chg Q | 23.3% |
| QoQ Delta Rev Chg LTM | 6.4% |
| Op Inc Chg LTM | 8.4% |
| Op Inc Chg 3Y Avg | 62.5% |
| Op Mgn LTM | 9.9% |
| Op Mgn 3Y Avg | 5.8% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 17.7% |
| CFO/Rev 3Y Avg | 15.0% |
| FCF/Rev LTM | 9.0% |
| FCF/Rev 3Y Avg | 3.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 1.2 |
| P/Op Inc | 24.9 |
| P/EBIT | 7.6 |
| P/E | 10.1 |
| P/CFO | 16.4 |
| Total Yield | 3.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.5% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.7% |
| 3M Rtn | -11.8% |
| 6M Rtn | -30.5% |
| 12M Rtn | -31.4% |
| 3Y Rtn | 11.6% |
| 1M Excs Rtn | -9.2% |
| 3M Excs Rtn | -15.6% |
| 6M Excs Rtn | -37.5% |
| 12M Excs Rtn | -67.6% |
| 3Y Excs Rtn | -60.0% |
Price Behavior
Price Behavior
| Market Price | $3.31 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 06/24/2008 | |
| Distance from 52W High | -58.4% | |
| 50 Days | 200 Days | |
| DMA Price | $4.37 | $6.16 |
| DMA Trend | down | down |
| Distance from DMA | -24.2% | -46.2% |
| 3M | 1YR | |
| Volatility | 40.0% | 42.0% |
| Downside Capture | 1.24 | 1.02 |
| Upside Capture | 51.59 | 67.18 |
| Correlation (SPY) | 38.3% | 31.0% |
MDXG Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.79 | 1.42 | 1.06 | 1.12 | 0.79 | 0.79 |
| Up Beta | 2.53 | 1.24 | 1.55 | 0.77 | 0.53 | 0.68 |
| Down Beta | 1.97 | 1.79 | 0.76 | 1.13 | 0.85 | 0.86 |
| Up Capture | 65% | 63% | -27% | 39% | 47% | 55% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 7 | 16 | 21 | 51 | 106 | 354 |
| Down Capture | 215% | 174% | 204% | 160% | 128% | 97% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 14 | 25 | 41 | 72 | 137 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -51.6% | 41.8% | -1.63 | - |
| Sector ETF (XLV) | 12.0% | 15.9% | 0.52 | 32.1% |
| Equity (SPY) | 26.7% | 12.5% | 1.77 | 34.2% |
| Gold (GLD) | 38.9% | 27.4% | 1.19 | 6.1% |
| Commodities (DBC) | 23.5% | 16.2% | 1.32 | -7.9% |
| Real Estate (VNQ) | 15.6% | 13.6% | 0.82 | 16.5% |
| Bitcoin (BTCUSD) | -12.8% | 42.6% | -0.21 | 16.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -23.7% | 62.1% | -0.15 | - |
| Sector ETF (XLV) | 5.6% | 14.6% | 0.20 | 27.7% |
| Equity (SPY) | 10.5% | 17.1% | 0.48 | 34.7% |
| Gold (GLD) | 21.5% | 17.8% | 0.99 | 2.6% |
| Commodities (DBC) | 10.7% | 18.8% | 0.47 | 2.1% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 28.7% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 13.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -15.7% | 67.4% | 0.04 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 24.6% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 28.8% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | 2.9% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 7.4% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 24.2% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 7.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/25/2026 | -6.4% | -8.7% | -25.4% |
| 10/29/2025 | 2.9% | 10.7% | -7.2% |
| 7/30/2025 | 10.3% | 11.0% | 10.1% |
| 2/26/2025 | 1.6% | 0.9% | -3.4% |
| 10/30/2024 | 20.4% | 31.8% | 62.6% |
| 7/31/2024 | -10.3% | -15.8% | -10.2% |
| 2/28/2024 | -0.5% | -1.6% | -6.1% |
| 10/30/2023 | 3.8% | 5.9% | 23.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 7 |
| # Negative | 8 | 8 | 10 |
| Median Positive | 5.4% | 10.7% | 20.5% |
| Median Negative | -5.1% | -6.9% | -6.6% |
| Max Positive | 20.4% | 31.8% | 62.6% |
| Max Negative | -13.0% | -15.8% | -29.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 10/30/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/03/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 340.00 Mil | 350.00 Mil | 360.00 Mil | Higher New | |||
| 2026 Operating Margin | 20.0% | 21.0% | -6.7% | -1.5% | Lowered | Guidance: 22.5% for 2025 | |
| 2026 Revenue Growth | 12.0% | 9.1% | 1.0% | Raised | Guidance: 11.0% for 2025 | ||
Prior: Q3 2025 Earnings Reported 10/29/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue Growth | 11.0% | 12.0% | 13.0% | 9.1% | 1.0% | Raised | Guidance: 11.0% for 2025 |
| 2025 Adjusted EBITDA Margin | 22.0% | 22.5% | 23.0% | 12.5% | 2.5% | Raised | Guidance: 20.0% for 2025 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.